139 related articles for article (PubMed ID: 35753824)
1. Renin Production by Juxtaglomerular Cell Tumors and Clear Cell Renal Cell Carcinoma and the Role of Angiotensin Signaling Inhibitors.
Gupta S; Nichols P; Lohse CM; Kosari F; Kattah AG; Harris FR; Karagouga G; Mehra R; Fine SW; Reuter VE; Herrera-Hernandez L; Zganjar AJ; Britton CJ; Potretzke AM; Boorjian SA; Thompson RH; Jimenez RE; Leibovich BC; Garovic VD; Cheville JC; Sharma V
Mayo Clin Proc; 2022 Nov; 97(11):2050-2064. PubMed ID: 35753824
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin Inhibitors as Treatment of Sunitinib/Pazopanib-induced Hypertension in Metastatic Renal Cell Carcinoma.
Penttilä P; Rautiola J; Poussa T; Peltola K; Bono P
Clin Genitourin Cancer; 2017 Jun; 15(3):384-390.e3. PubMed ID: 28089721
[TBL] [Abstract][Full Text] [Related]
3. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.
Rini BI; Cohen DP; Lu DR; Chen I; Hariharan S; Gore ME; Figlin RA; Baum MS; Motzer RJ
J Natl Cancer Inst; 2011 May; 103(9):763-73. PubMed ID: 21527770
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials.
Sorich MJ; Kichenadasse G; Rowland A; Woodman RJ; Mangoni AA
Int J Cancer; 2016 May; 138(9):2293-9. PubMed ID: 26685869
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.
de Velasco G; McKay RR; Lin X; Moreira RB; Simantov R; Choueiri TK
Clin Genitourin Cancer; 2017 Dec; 15(6):652-660.e1. PubMed ID: 28410911
[TBL] [Abstract][Full Text] [Related]
6. Prognostic role of the immunohistochemical expression of proteins related to the renin-angiotensin system pathway in nonmetastatic clear cell renal cell carcinoma.
Mourão TC; Bezerra SM; de Almeida E Paula F; Rocha MM; Santos VE; Brazão Junior ES; Abreu D; da Costa WH; Zequi SC
Urol Oncol; 2023 Aug; 41(8):359.e1-359.e13. PubMed ID: 37286405
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination.
Keizman D; Huang P; Eisenberger MA; Pili R; Kim JJ; Antonarakis ES; Hammers H; Carducci MA
Eur J Cancer; 2011 Sep; 47(13):1955-61. PubMed ID: 21600760
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
[TBL] [Abstract][Full Text] [Related]
9. Favorable response to combination treatment of cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin system inhibitor in metastatic renal cell carcinoma: Report of three cases.
Tatokoro M; Fujii Y; Kawakami S; Fukui N; Komai Y; Saito K; Koga F; Morimoto S; Fukui I; Kihara K
Int J Urol; 2008 Sep; 15(9):848-50. PubMed ID: 18786206
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
[TBL] [Abstract][Full Text] [Related]
11. Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery.
Leibovich BC; Lohse CM; Cheville JC; Zaid HB; Boorjian SA; Frank I; Thompson RH; Parker WP
Eur Urol; 2018 May; 73(5):772-780. PubMed ID: 29398265
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Impact of Renin-Angiotensin System Blockade on Renal Cell Carcinoma After Surgery.
Miyajima A; Yazawa S; Kosaka T; Tanaka N; Shirotake S; Mizuno R; Kikuchi E; Oya M
Ann Surg Oncol; 2015 Oct; 22(11):3751-9. PubMed ID: 25691280
[TBL] [Abstract][Full Text] [Related]
13. Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.
Rautiola J; Donskov F; Peltola K; Joensuu H; Bono P
BJU Int; 2016 Jan; 117(1):110-7. PubMed ID: 25252180
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical expression of renin is a prognostic factor for recurrence in nonmetastatic renal cell carcinoma.
de Almeida E Paula F; Bezerra SM; da Cunha IW; Munhoz GC; Abreu D; Lara PN; da Costa WH; Zéqui SC
Urol Oncol; 2019 Dec; 37(12):947-954. PubMed ID: 31473089
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of beta-blockers and survival among hypertensive patients with renal cell carcinoma.
Parker WP; Lohse CM; Zaid HB; Cheville JC; Boorjian SA; Leibovich BC; Thompson RH
Urol Oncol; 2017 Jan; 35(1):36.e1-36.e6. PubMed ID: 27687543
[TBL] [Abstract][Full Text] [Related]
16. The utility of PAX-2 in distinguishing metastatic clear cell renal cell carcinoma from its morphologic mimics: an immunohistochemical study with comparison to renal cell carcinoma marker.
Gokden N; Gokden M; Phan DC; McKenney JK
Am J Surg Pathol; 2008 Oct; 32(10):1462-7. PubMed ID: 18685487
[TBL] [Abstract][Full Text] [Related]
17. Histological subtype of renal cell carcinoma significantly affects survival in the era of partial nephrectomy.
Nguyen DP; Vertosick EA; Corradi RB; Vilaseca A; Benfante NE; Touijer KA; Sjoberg DD; Russo P
Urol Oncol; 2016 Jun; 34(6):259.e1-8. PubMed ID: 26947350
[TBL] [Abstract][Full Text] [Related]
18. Clear cell papillary renal cell carcinoma is the fourth most common histologic type of renal cell carcinoma in 290 consecutive nephrectomies for renal cell carcinoma.
Zhou H; Zheng S; Truong LD; Ro JY; Ayala AG; Shen SS
Hum Pathol; 2014 Jan; 45(1):59-64. PubMed ID: 24182559
[TBL] [Abstract][Full Text] [Related]
19. Oncological outcomes of minimally invasive partial versus minimally invasive radical nephrectomy for cT1-2/N0/M0 clear cell renal cell carcinoma: a propensity score-matched analysis.
Simone G; Tuderti G; Anceschi U; Papalia R; Ferriero M; Misuraca L; Minisola F; Mastroianni R; Costantini M; Guaglianone S; Sentinelli S; Gallucci M
World J Urol; 2017 May; 35(5):789-794. PubMed ID: 27578234
[TBL] [Abstract][Full Text] [Related]
20. How often are patients with diabetes or hypertension being treated with partial nephrectomy for renal cell carcinoma? A population-based analysis.
Abouassaly R; Finelli A; Tomlinson GA; Urbach DR; Alibhai SM
BJU Int; 2011 Dec; 108(11):1806-12. PubMed ID: 21599823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
